A mechanism underlying the anti‐inflammatory action of piceatannol

Han Jin Cho,Jin‐Kyung Kim,Hong‐Seob So,Jung Han Yoon Park
DOI: https://doi.org/10.1096/fasebj.23.1_supplement.910.6
2009-04-01
The FASEB Journal
Abstract:Piceatannol (3,4,3',5′‐tetrahydroxy‐trans‐stilbene) is a derivative of resveratrol with a variety of biological activities including anti‐inflammatory, anti‐proliferative, and anti‐cancer activity. We assessed the mechanisms by which piceatannol inhibits inflammatory responses using lipopolysaccharide (LPS)‐treated Raw264.7 murine macrophages. Piceatannol (0 ‐ 10 μmol/L) decreased LPS‐induced release of nitric oxide, which was accompanied by decreases in the expression of the iNOS protein. The activations of NF‐κB, AP‐1, and STAT3 are crucial steps in the transcriptional activation of the iNOS. Piceatannol prevented LPS‐induced degradation of inhibitor of κBα, translocation of p65 to the nucleus, and phosphorylation of SAPK/JNK. Also, piceatannol inhibited the phosphorylation of STAT3 and translocation of STAT3 to the nucleus. In addition, piceatannol increased the protein and mRNA levels of hemeoxygenase (HO)‐1, the rate‐limiting enzyme of heme catabolism which plays a critical role in mediating antioxidant and anti‐inflammatory effects. Piceatannol inhibited ARE‐driven luciferase activity in Raw cells transfected with an ARE‐luciferase reporter construct containing the enhancer 2 and minimal promoter region of HO‐1. These results suggest that piceatannol exerts anti‐inflammatory effects via the downregulation of iNOS expression and uregulation of HO‐1 expression.
What problem does this paper attempt to address?